Daplozmet (dapagliflozin + metformin): Uses, Dosage & Side Effects

What it's for (Indications)

Dapagliflozin + metformin, often marketed under brand names such as Dapa-Met, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
This combination therapy is particularly useful for patients who have not achieved adequate glycemic control with either dapagliflozin or metformin monotherapy, or for those already treated with both individual components.
Dapagliflozin, an SGLT2 inhibitor, has also demonstrated benefits in reducing the risk of cardiovascular death, hospitalization for heart failure, and progression of kidney disease in patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.
The inclusion of metformin, a biguanide, further enhances blood glucose lowering through distinct mechanisms, making this a potent and comprehensive option for managing complex type 2 diabetes.

Dosage Information

Type	Guideline
Standard	The dosage of dapagliflozin + metformin must be individualized based on the patient's current regimen, effectiveness, and tolerability, while not exceeding the maximum recommended daily dose of each component. Typically, initial therapy for patients not currently on metformin may start with dapagliflozin 5 mg and metformin 500 mg, taken orally twice daily. For patients already on metformin, the initial dose should provide dapagliflozin 5 mg and a metformin dose similar to the current regimen, taken twice daily. The dose of dapagliflozin can be increased to a maximum of 10 mg twice daily, and metformin can be increased up to a maximum of 2000 mg daily (typically 1000 mg twice daily), always guided by glycemic response and tolerability. Administration should occur with meals to mitigate gastrointestinal side effects associated with metformin. Renal function must be assessed prior to initiating treatment and periodically thereafter, as dosage adjustments or discontinuation may be necessary in patients with declining renal function.

Type

Guideline

Standard

The dosage of dapagliflozin + metformin must be individualized based on the patient's current regimen, effectiveness, and tolerability, while not exceeding the maximum recommended daily dose of each component. Typically, initial therapy for patients not currently on metformin may start with dapagliflozin 5 mg and metformin 500 mg, taken orally twice daily. For patients already on metformin, the initial dose should provide dapagliflozin 5 mg and a metformin dose similar to the current regimen, taken twice daily. The dose of dapagliflozin can be increased to a maximum of 10 mg twice daily, and metformin can be increased up to a maximum of 2000 mg daily (typically 1000 mg twice daily), always guided by glycemic response and tolerability. Administration should occur with meals to mitigate gastrointestinal side effects associated with metformin. Renal function must be assessed prior to initiating treatment and periodically thereafter, as dosage adjustments or discontinuation may be necessary in patients with declining renal function.

Safety & Warnings

Common Side Effects

Common side effects associated with dapagliflozin + metformin include gastrointestinal disturbances such as diarrhea, nausea, vomiting, and abdominal discomfort, primarily attributed to the metformin component.
Other frequently reported adverse reactions related to dapagliflozin include genital mycotic infections (e.
g.
, vulvovaginitis, balanitis) and urinary tract infections, often due to increased glucose excretion in the urine.
Patients may also experience increased urination (polyuria) and thirst.
Less common but serious side effects can include hypoglycemia, especially when used in combination with insulin or sulfonylureas, and volume depletion potentially leading to orthostatic hypotension or dizziness.
Rare but severe adverse events include diabetic ketoacidosis (DKA), Fournier's gangrene, and acute kidney injury.
Lactic acidosis, though rare, is a potentially fatal complication associated with metformin, warranting careful patient selection and monitoring.

Serious Warnings

Black Box Warning: The metformin component of dapagliflozin + metformin carries a Black Box Warning regarding the risk of lactic acidosis. Lactic acidosis is a rare but serious metabolic complication that can occur due to metformin accumulation during treatment, particularly in patients with impaired renal function. The condition is characterized by elevated blood lactate levels (>5 mmol/L), anion gap acidosis, and an increased lactate/pyruvate ratio. Symptoms include malaise, myalgia, respiratory distress, somnolence, and non-specific abdominal discomfort. In severe cases, hypothermia, hypotension, and resistant bradyarrhythmias may occur. Risk factors for lactic acidosis include significant renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors), advanced age, hypoxic states (e.g., acute congestive heart failure, sepsis), excessive alcohol intake, hepatic impairment, and acute decompensated heart failure. If lactic acidosis is suspected, Dapa-Met should be discontinued immediately, and supportive measures, including hemodialysis, should be instituted promptly. Renal function should be assessed prior to initiation and at least annually thereafter, or more frequently in patients at risk of renal impairment.
Several critical warnings are associated with dapagliflozin + metformin therapy.
Patients should be monitored for signs and symptoms of volume depletion, particularly in those with renal impairment, the elderly, or those on loop diuretics, as dapagliflozin can cause osmotic diuresis leading to hypotension.
Renal function should be assessed before initiation and monitored periodically during treatment, as both components rely on renal excretion and can be affected by renal impairment.
The risk of developing diabetic ketoacidosis (DKA) is present with SGLT2 inhibitors, even in patients with only moderately elevated blood glucose levels; patients experiencing symptoms such as nausea, vomiting, abdominal pain, or fatigue should seek immediate medical attention.
Serious genital mycotic infections and complicated urinary tract infections, including urosepsis and pyelonephritis, have been reported.
Rare but life-threatening cases of Fournier's gangrene (necrotizing fasciitis of the perineum) have also been reported with SGLT2 inhibitors, requiring urgent surgical intervention.
Vitamin B12 deficiency can occur with long-term metformin use, necessitating periodic monitoring.

How it Works (Mechanism of Action)

Dapagliflozin + metformin combines two distinct and complementary mechanisms of action to improve glycemic control in type 2 diabetes. Dapagliflozin is a selective inhibitor of the sodium-glucose co-transporter 2 (SGLT2) located in the renal tubules. By inhibiting SGLT2, dapagliflozin reduces glucose reabsorption from the glomerular filtrate and lowers the renal threshold for glucose, thereby increasing urinary glucose excretion and subsequently lowering plasma glucose concentrations independently of insulin secretion. Metformin hydrochloride is a biguanide that acts primarily by decreasing hepatic glucose production, largely by inhibiting gluconeogenesis. It also enhances insulin sensitivity by increasing peripheral glucose uptake and utilization in skeletal muscle, and reduces intestinal absorption of glucose. Metformin does not stimulate insulin secretion and therefore typically does not cause hypoglycemia when used as monotherapy. The synergistic action of these two agents provides comprehensive glucose lowering through both renal and hepatic/peripheral pathways.